



2023 WuXi AppTec Investor Day

WuXi Chemistry:

A Global Leading CRDMO Platform

Minzhang Chen, Ph.D.

Co-CEO

Forward-Looking Statements

This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our clients’ intellectual property, unforeseeable international tension, competition, the impact of emergencies and other force majeure. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this presentation is as of the date of this presentation and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Non-IFRS Financial Measures

We provide non-IFRS gross profit and non-IFRS net profit attributable to owners of the Company, which exclude share-based compensation expenses, listing expenses and issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses and amortization of intangible assets acquired in business combinations, non-financial assets impairment, etc. We also provide adjusted non-IFRS net profit attributable to owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture capital investments and joint ventures. Neither of above is required by, or presented in accordance with IFRS.

We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such non-IFRS financial measures, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

WuXi Chemistry: a global leading CRDMO for all synthetic molecules



Jingchao Dong
Ph.D.

Research Chemistry

Medicinal Chemistry, Library and Custom Synthesis, Catalog Products, Discovery Process Chemistry



Xiaoyong Fu
Ph.D.

Small Molecule API

Process Development, Manufacturing



Jinling Chen
Ph.D.

Drug Product

Solid State, Pre-formulation, Formulation, Manufacturing, Packaging, Labeling, Distribution



Yu Lu

WuXi TIDES

Oligonucleotides, Peptides, Conjugates, Amidites, Unnatural Amino Acids, Linkers, Ligands

Global Platform. Global Talents.


17
sites

24,598
employees

2,354
clients


01

CRDMO Business Model Drives Sustained High Growth




Business far outgrew the industry average

2015-2023 WuXi Chemistry Revenue
(RMB ¥ 100 Million)




Sustained revenue growth

WuXi Chemistry Revenue
(RMB ¥ 100 Million)




WuXi Chemistry Revenue
Excluding COVID-19 Commercial Projects
(RMB ¥ 100 Million)



Leading chemistry-based CRDMO market in China

Higher chemistry-based service revenue and growth than 4 major competitors combined



Total revenue of 4 competitors in 2022 is 24,352 ¥ Million RMB, 85.5% increase vs. 2021


Source: chemistry related revenue from company annual reports and investor analysis reports

Growing small molecule CRDMO pipeline

“R” 19%↑

“D” 40%↑

“M” 30%↑




16%
of global clinical stage drugs
June 30, 2023

% growth of molecules in each stage
June 2023 vs. June 2022

New molecules entered each
phase in **2023H1**

Produced 7 out of 15 small molecules approved by US FDA in 2023H1

US FDA New Drug Approvals by Modality (2023H1)



Produced **47%** of new drugs approved in 2023 H1



Produced 5 out of 10 best-selling small molecule drugs



5 out of 10

\$50+ billion

combined global sales of these 5 drugs in 2022

Data Source: *Top 200 Small Molecule Drugs by Retail Sales in 2022*
Complied by the Njarðarson Group (The University of Arizona)

Capturing fast growing Glucagon-Like Peptide-1 Agonists (GLP-1) market

Currently Producing **11** GLP-1 Drugs



Estimated global sales of GLP-1 drugs in 2028 will reach **\$ 62.4B**, **2.6X** of the sales in 2022*

*Source: Evaluate Pharma, Glucagon-like peptide 1 (GLP-1) receptor agonist : Worldwide | Market Size by MoA.

Growing clients across CRDMO value chain

C“R”DMO

CR“DM”O





2,354

WuXi Chemistry clients

+17% vs. 2022H1

CRDMO model enabled us to follow the clients at early stage

Number of Clients Converted from “R” to “R+DM”



“R”: client using discovery services only

“R+DM”: client using discovery, development and manufacturing services

“DM”: client using development and manufacturing services

Why clients come to WuXi Chemistry

Visionary Leaders

- Pioneers of CRDMO business model
- Insights into the industry, XDC and TIDES etc.

“One-Stop” Capability

- All synthetic modalities
- Full life cycle of drug discovery and development capabilities

Unparalleled Capacity

- 25,000 people and 17 sites
- Largest CRDMO in the world

Quality System

- 70+ health authority inspections with 100% success rate
- Including FDA, EMA, NMPA

Speed

1.5 ~ 2X

Reliability

100% success rate

02

**Investment in China, US, Europe and Singapore
Continues to Grow, Further Strengthening Our
Global “R” “D” and “M” Network**

17 sites across the globe



China

- Shanghai Waigaoqiao **R** **D** **M**
- Shanghai Zhangjiang **R**
- Tianjin **R** **D**
- Wuhan, Hubei **R** **D**
- Chengdu, Sichuan **R**
- Qidong, Jiangsu **R**
- Shanghai Jinshan **D** **M**
- Changzhou, Jiangsu **D** **M**
- Changshu, Jiangsu **M**
- Taixing #1, Jiangsu **M**
- Taixing #2, Jiangsu **M**
- Wuxi City, Jiangsu **D** **M**



United States

- San Francisco, CA **R**
- San Diego, CA **D** **M**
- Middletown, DE **D** **M**



Switzerland

- Couvet, Neuchâtel **M**



Singapore

- Tuas Singapore **R** **D** **M**

R Research 8

D Development 9

M Manufacturing 11

Changzhou API site expansion completed

6 new plants commissioned
2022 – 2023



74

acres

~2,000

scientists

~2,000 m³

total reactor volume

All Synthetic Molecular Modalities

- Small molecules
- Oligonucleotides
- Peptides

Enabling Technology

- HPAPI
- Flow Chemistry
- Spray Dried Dispersion
- Preparative HPLC and SFC

Taixing site to be opened in H2 2023

Total area: 169 Acres

Phase I: 81 Acres



1st plant
to be opened in H2 2023

1,000+ m³
total reactor volume

All Synthetic Molecular Modalities
Small molecules | Oligonucleotides | Peptides

Couvet Switzerland drug product site expansion



Producing one of top-5 best-selling small molecule drugs to 9 markets



New Capabilities

by 2025

- Spray dried dispersion
- Parental formulation manufacturing line
- Lipid nanoparticle (LNP)

Capacity Expansion

2X oral dose
capacity in 2024

2X packaging
capacity by 2025

Middletown USA construction progress



Total Area: 190 acres

Phase I
open in 2026

- Formulation Development
- Clinical and Commercial Drug Product Manufacturing
- Packaging, Labeling and Distribution



Singapore Tuas site to be opened in 2026



Total area: 50 acres 7 plants planned

Phase I

R&D Center

Process Chemistry Center of Excellence

Research chemistry

Manufacturing


2 small molecule plants

1 TIDES (oligonucleotide and peptide) plant

“End-to-end” supply chain for oligonucleotide therapies including amidites, APIs and conjugates

03

WuXi TIDES (Oligonucleotide and Peptide) Achieved Unprecedented Growth, Leading the Industry Across Synthesis, Drug Product and Drug Delivery



The background features several 3D molecular models. On the left, a DNA double helix is rendered in white and light blue. In the center, a complex protein structure is shown in orange and red. On the right, a smaller protein structure is depicted in light blue. A blue horizontal line with a downward-pointing arrowhead is positioned below the main text.

WuXi TIDES revenue achieved unprecedented growth




WuXi TIDES Revenue
(RMB ¥ 100 Million)




Rapid TIDES “DM” business growth

TIDES “DM” Molecules




TIDES “DM” Clients




Fast growing peptide production

Solid Phase Peptide Synthesizer Total Reactor Volume (liter)



Peptide Product Produced (kilogram)



Strengthened Drug Product offerings to further boost TIDES growth



Injectable

(Wuxi City, Couvet, Middletown)

- Small molecule, oligonucleotide and peptide
- Highly potent molecules
- Fully enclosed and robotic filling

130+ projects



Lipid Nanoparticle


(Wuxi City, Couvet, Middletown)

- End-to-end services: lipid synthesis, LNP formulation development and GMP production

20+ projects

Increasing synergy between API and Drug Product services for TIDES molecules

TIDES Molecules Using Both API and Drug Product Services



- Number of TIDES molecules using both API and drug produce services
- % TIDES molecules in our pipeline using both API and drug product services

WuXi Chemistry

Global leading CRDMO
with “one stop” capability
and unparalleled capacity

Unique CRDMO
business model will
continue to drive our
strong growth

TIDES is bringing in
the next wave of
accelerated growth